MCRB | Seres Therapeutics Inc
Category: Consumer goods
Quick infos Headquarters: Massachusetts, United States Trade prices Volume: Market Cap: 334.8M Prev closed: Open: 5.81 High: 5.86 Low: 5.52 52 week low: 5.41 52 week high: 25.06 Dividends: No Dividends Next ER: May 9, 2023 Before Market Opens
Earnings History Date EPS / Forecast Revenue / Forecast August 1, 2023 May 9, 2023 -0.57 / -0.55-522K / 1.8MMarch 7, 2023 -0.51 / -0.455974K / 6MBeat! November 2, 2022 -0.49 / -0.46883.44M / 7MAugust 3, 2022 -0.7 / -0.59631.22M / 4.54Mview more
Historical Data Date Price Open High Low Vol Change ER May 8, 2023 5.56 6.05 6.08
5.47
4.3M -5.92% May 5, 2023 5.91 5.58 5.94
5.5
3.8M 8.44% May 4, 2023 5.45 5.06 5.51
4.91
3.3M 4.41% May 3, 2023 5.22 4.7 5.45
4.7
5.7M 11.78% May 2, 2023 4.67 4.86 5.13
4.55
4.7M -4.11% May 1, 2023 4.87 4.86 4.9
4.51
6.3M -0.2% Apr 28, 2023 4.88 5.19 5.34
4.87
10.0M -8.27% Apr 27, 2023 5.32 6.6 6.65
5.27
20.6M -16.88% Apr 26, 2023 6.4 6.24 6.47
5.97
5.4M 3.90% Apr 25, 2023 6.16 6.46 6.73
6.01
5.8M -5.23% view more
MCRB
More profiles and info about the company News
Seres Therapeutics (MCRB) Reports Q4 Loss, Misses Revenue Estimates finance.yahoo.com Mar 24, 2023 8:25 am
Seres Therapeutics (MCRB) Moves 10.9% Higher: Will This Strength Last? finance.yahoo.com Mar 22, 2023 3:44 am
Seres Therapeutics, Inc. (NASDAQ:MCRB) Q4 2022 Earnings Call Transcript finance.yahoo.com Mar 8, 2023 10:45 pm Seres Therapeutics falls 9% on full-year earnings miss seekingalpha.com Mar 8, 2023 1:20 am Seres Therapeutics GAAP EPS of -$2.31 misses by $0.15, revenue of $7.13M misses by $6.62M seekingalpha.com Mar 7, 2023 8:01 pm Seres Therapeutics FY 2022 Earnings Preview seekingalpha.com Mar 7, 2023 12:14 am
Seres Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) finance.yahoo.com Mar 3, 2023 4:00 pm
Seres Therapeutics to Participate in Cowen 43rd Annual Health Care Conference finance.yahoo.com Feb 27, 2023 7:00 am
Seres Therapeutics Announces Initiation of Enrollment in SER-155 Phase 1b Study Cohort 2 in Individuals Undergoing Allogeneic Hematopoietic Stem Cell Transplantation finance.yahoo.com Feb 8, 2023 7:28 am
Seres Therapeutics' (NASDAQ:MCRB) investors will be pleased with their respectable 70% return over the last three years finance.yahoo.com Jan 28, 2023 7:51 am
Seres Therapeutics to Host Investor Webcast on December 8, 2022 to Discuss SER-109 Commercial Strategy finance.yahoo.com Nov 22, 2022 4:01 pm Seres stock sinks as Q3 plunges in loss seekingalpha.com Nov 3, 2022 1:03 am Seres Therapeutics GAAP EPS of -$0.49 misses by $0.02, revenue of $3.44M misses by $3.57M seekingalpha.com Nov 2, 2022 7:10 pm
Seres Therapeutics (MCRB) Reports Q3 Loss, Lags Revenue Estimates finance.yahoo.com Nov 2, 2022 8:35 am
Seres Therapeutics to Host Third Quarter 2022 Financial Results and Operational Progress Conference Call and Webcast on November 2, 2022 finance.yahoo.com Oct 27, 2022 7:00 am Seres microbiome therapy for bacterial infection gets FDA priority review seekingalpha.com Oct 26, 2022 8:09 pm
Seres Therapeutics Appoints Genomic Medicine and Microbiology Pioneer Claire M. Fraser, Ph.D., to its Board of Directors and Announces SER-155 Phase 1b Study Progress finance.yahoo.com Jan 5, 2023 7:00 am
Seres Therapeutics Presents SER-109 ECOSPOR IV Study Data at IDWeek and American College of Gastroenterology (ACG) 2022 Annual Meetings finance.yahoo.com Oct 23, 2022 3:30 pm
Seres Therapeutics to Present Clinical Results at IDWeek and American College of Gastroenterology (ACG) 2022 Annual Meeting finance.yahoo.com Oct 12, 2022 7:00 am
Seres Therapeutics Reports Second Quarter 2022 Financial Results and Provides Business Updates finance.yahoo.com Sep 17, 2022 7:00 am This company doesn't provide a dividend.
Talk about Seres Therapeutics Inc below in comments section below. Do you think you'll buy? Do you already have active trades now?
EarningsAhead is not affiliated with and this is not an endorsement of the companies featured above. This profile is based on publicly available information and is intended to be informative in nature. Most of the datas are collected by our Data Entry and we aim to be as accurate as humanly possible.
Share it with fellow traders:
or join discussions in FB below
(
FB comments )
If you are looking for News & events, Press Release, they are available on their Investors Relations site.
Consensus BUY 100 HOLD 0 SELL 0
If you want to help pay for server cost or for improving this tool. You can send it via Paypal . More features coming soon :)
Buy on Amazon Graham's philosophy of "value investing" has made The Intelligent Investor the stock market bible ever since its original publication in 1949.
The best book on investing ever written. -- Warren Buffet